



The TIMI Trials

TIMI 12

OBJECTIVE: To evaluate the safety and efficacy of the oral GP IIb/IIIa inhibitor sibrافiban for the treatment of patients with a recent acute coronary syndrome.

1. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrافiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. *Thrombolysis in Myocardial Infarction. Circulation* 1998;97:340-9.
2. Cannon CP, Bray PF, Ault KA, Rizzo MJ, Braunwald E. PIA2 polymorphism of the platelet IIb/IIIa receptor: increased risk of early recurrent ischemic events in acute coronary syndromes, increased platelet aggregability, and effective platelet inhibition by an oral IIb/IIIa inhibitor: results from TIMI 12. *Circulation* 1998;98(Suppl. I):I-171.
3. Ault KA, Cannon CP, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. *Thrombolysis in Myocardial Infarction. J Am Coll Cardiol* 1999;33:634-9.